top of page


Before Oculogica, diagnosing a concussion was more of an art than a science.  A patient would be asked whether they had a headache, fatigue, or nausea along with a host of other questions in a 15 to 25 minute exchange.

The Oculogica EyeBOX® test, on the other hand, takes only four minutes. It utilizes a near-infrared camera to track eye movements while a patient watches a video. The camera records gaze positions 500 times per second. An algorithm then computes a BOX score. A score of 10 or higher indicates a concussion.  The EyeBOX® is the first objective diagnostic cleared by the FDA as an aid in the diagnosis of concussion. The test is non-invasive, does not rely on the patient’s literacy level, and can be used in both pediatrics and adults, for injuries due to any type of activity.


"Our partnership with Sleman & Lund has been exceptional from the outset. Our technology is complex, but we are confident in Peter and the rest of the team.  They are truly dedicated to their craft.  The relationship with the firm is not transactional, but a real partnership built on trust."

Rosina Samadani, CEO of Oculogica

The original EyeBOX received FDA De Novo classification in 2018, with subsequent versions cleared by the FDA through the 510(k) pathway in 2019 and 2020. These versions incorporated improvements like the addition of Wi-Fi, transitioning from a wheeled chassis to a tabletop enclosure, and other enhancements.

Not surprisingly, many have taken notice, including glowing profiles in The New York Times and Forbes.  More information can be found at


pending applications


issued patents

bottom of page